Braveheart Bio's Phase 3 LIONHEART-HCM trial recruiting for BHB-1893 in oHCM
Braveheart Bio is recruiting patients for a Phase 3 trial comparing BHB-1893 to metoprolol in symptomatic obstructive hypertrophic cardiomyopathy.
Braveheart Bio has one active registry update this week, concerning its lead Phase 3 cardiomyopathy trial.
- Braveheart Bio, Inc. sponsors "LIONHEART-HCM" (NCT07755904), a Phase 3 trial testing BHB-1893 compared to metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy.1 The study is recruiting, with an estimated enrollment of 210 participants and a primary endpoint of change from baseline in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing at week 24.1 The trial is running at three sites in the United States, located in Manhasset, New York; Rock Hill, South Carolina; and Plano, Texas.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.